American Society of Clinical Oncology Annual Meeting

American Society of Clinical Oncology Annual Meeting
Name	American Society of Clinical Oncology Annual Meeting
Abbreviation	ASCO Annual Meeting
Established	1964
Frequency	Annual
Location	Varies (frequently Chicago, San Francisco, Orlando)
Organizer	American Society of Clinical Oncology

Contents

American Society of Clinical Oncology Annual Meeting The American Society of Clinical Oncology Annual Meeting is a major yearly gathering that convenes oncology clinicians, researchers, industry leaders, regulators, and patient advocates from around the world. It serves as a forum for presentation of peer-reviewed trials, approval-impacting data, and policy discussions that influence care delivered at institutions such as Mayo Clinic, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Johns Hopkins Hospital, and MD Anderson Cancer Center. The meeting typically attracts delegates connected to institutions like National Institutes of Health, Food and Drug Administration, European Society for Medical Oncology, and corporations such as Pfizer, Roche, and Merck & Co..

History

The Annual Meeting originated from gatherings organized by the American Society of Clinical Oncology in the 1960s, growing alongside landmark developments at centers including Roswell Park Comprehensive Cancer Center, Fred Hutchinson Cancer Center, and Stanford Cancer Institute. Over decades the event paralleled pivotal moments involving investigators like James Allison, Emmanuelle Charpentier, and Françoise Barré-Sinoussi, and coincided with regulatory milestones from the Food and Drug Administration and legislative acts debated in the United States Congress. Expansion in the 1990s and 2000s brought collaborations with groups such as National Comprehensive Cancer Network, European Medicines Agency, and foundations including Susan G. Komen and American Cancer Society.

Program governance involves committees with representatives from academic centers including Yale School of Medicine, University of Pennsylvania School of Medicine, and Columbia University Irving Medical Center, professional organizations like Association of American Medical Colleges, and regulatory liaisons from Centers for Medicare & Medicaid Services. The format includes plenaries, oral abstract sessions, poster sessions, education tracks, and industry symposia, with venues rotating among cities such as Chicago, San Francisco, and Orlando. Industry exhibition halls feature companies like AstraZeneca, Bristol-Myers Squibb, Novartis, and GlaxoSmithKline, while patient advocacy groups including Leukemia & Lymphoma Society and Cancer Research UK host satellite events.

The scientific program highlights randomized controlled trials, translational research, and real-world evidence from collaborations with consortia such as SWOG Cancer Research Network, EORTC, and Alliance for Clinical Trials in Oncology. Sessions present data involving modalities developed at centers like Cold Spring Harbor Laboratory, Broad Institute, and Salk Institute for Biological Studies, and often feature investigators who have affiliations with Harvard Medical School, Oxford University, Imperial College London, and University of Tokyo. Major plenary trials frequently shape approvals by the Food and Drug Administration and guidance from organizations like National Institute for Health and Care Excellence.

Landmark findings presented at the meeting have included immunotherapy trials tied to researchers such as James P. Allison and Tasuku Honjo and targeted therapy advances involving companies Genentech and Amgen. Data on agents like PD-1 inhibitors reshaped practice at institutions including Cleveland Clinic and Mount Sinai Health System, while genomic medicine reports from collaborations with The Cancer Genome Atlas and International Agency for Research on Cancer informed precision oncology approaches used at Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. Breakthroughs in adjuvant therapy, liquid biopsy work from groups at University of California, San Diego, and survivorship studies linked to National Cancer Institute initiatives have all debuted at the meeting.

Attendance routinely numbers tens of thousands, with delegates from healthcare systems including Kaiser Permanente, academic hospitals such as Massachusetts General Hospital, and governments represented by delegations from Health Canada and Australian Department of Health. Corporate participation includes exhibit booths and sponsored symposia by Eli Lilly and Company, Takeda Pharmaceutical Company Limited, and Bayer AG, while philanthropic funding and grants come from entities like Bill & Melinda Gates Foundation and Wellcome Trust. Relationships with journal publishers such as New England Journal of Medicine, The Lancet, and Journal of Clinical Oncology amplify dissemination of highlighted data.

Findings presented at the meeting inform guideline committees including NCCN, American Society of Hematology, and European Society for Medical Oncology, influencing standards at hospitals like UCLA Health and policy at payers such as Blue Cross Blue Shield Association. Presentations have precipitated label changes by the Food and Drug Administration and reimbursement discussions with agencies like Centers for Medicare & Medicaid Services, affecting adoption of treatments at centers including City of Hope National Medical Center and Seattle Cancer Care Alliance.

The meeting has faced scrutiny over industry influence involving companies such as GlaxoSmithKline and Novartis and concerns raised by ethicists from institutions like Georgetown University Medical Center and Yale School of Medicine about conflicts of interest. Critics including representatives from Public Citizen and investigative reporting in outlets like The New York Times and The Wall Street Journal have highlighted issues around data transparency and selective reporting, prompting calls for greater openness from stakeholders such as BMJ and ProPublica. Debates over high-cost therapies presented by firms like Celgene and Gilead Sciences have led to discussions among policymakers in United States Congress and regulators at European Medicines Agency.

Category:Medical conferences